[{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"||Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001V","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by RhoVac AB
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
